Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response.
Thromboembolic events were described in patients with Chagas disease without cardiomyopathy. We aim to confirm if there is a hypercoagulable state in these patients and to determine if there is an early normalization of hemostasis factors after antiparasitic treatment. Ninety-nine individuals from C...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC4700971?pdf=render |
id |
doaj-2637f91cabf242139b92923e643da228 |
---|---|
record_format |
Article |
spelling |
doaj-2637f91cabf242139b92923e643da2282020-11-25T01:14:50ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352016-01-01101e000426910.1371/journal.pntd.0004269Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response.Maria-Jesus PinazoElizabeth de Jesus PosadaLuis IzquierdoDolors TassiesAlexandre-Ferreira MarquesElisa de LazzariEdelweiss AldasoroJose MuñozAlba AbrasSilvia TebarMontserrat GallegoIgor Correia de AlmeidaJoan-Carles ReverterJoaquim GasconThromboembolic events were described in patients with Chagas disease without cardiomyopathy. We aim to confirm if there is a hypercoagulable state in these patients and to determine if there is an early normalization of hemostasis factors after antiparasitic treatment. Ninety-nine individuals from Chagas disease-endemic areas were classified in two groups: G1, with T.cruzi infection (n = 56); G2, healthy individuals (n = 43). Twenty-four hemostasis factors were measured at baseline. G1 patients treated with benznidazole were followed for 36 months, recording clinical parameters and performance of conventional serology, chemiluminescent enzyme-linked immunosorbent assay (trypomastigote-derived glycosylphosphatidylinositol-anchored mucins), quantitative polymerase chain reaction, and hemostasis tests every 6-month visits. Prothrombin fragment 1+2 (F1+2) and endogenous thrombin potential (ETP) were abnormally expressed in 77% and 50% of infected patients at baseline but returned to and remained at normal levels shortly after treatment in 76% and 96% of cases, respectively. Plasmin-antiplasmin complexes (PAP) were altered before treatment in 32% of G1 patients but normalized in 94% of cases several months after treatment. None of the patients with normal F1+2 values during follow-up had a positive qRT-PCR result, but 3/24 patients (13%) with normal ETP values did. In a percentage of chronic T. cruzi infected patients treated with benznidazole, altered coagulation markers returned into normal levels. F1+2, ETP and PAP could be useful markers for assessing sustained response to benznidazole.http://europepmc.org/articles/PMC4700971?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Maria-Jesus Pinazo Elizabeth de Jesus Posada Luis Izquierdo Dolors Tassies Alexandre-Ferreira Marques Elisa de Lazzari Edelweiss Aldasoro Jose Muñoz Alba Abras Silvia Tebar Montserrat Gallego Igor Correia de Almeida Joan-Carles Reverter Joaquim Gascon |
spellingShingle |
Maria-Jesus Pinazo Elizabeth de Jesus Posada Luis Izquierdo Dolors Tassies Alexandre-Ferreira Marques Elisa de Lazzari Edelweiss Aldasoro Jose Muñoz Alba Abras Silvia Tebar Montserrat Gallego Igor Correia de Almeida Joan-Carles Reverter Joaquim Gascon Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response. PLoS Neglected Tropical Diseases |
author_facet |
Maria-Jesus Pinazo Elizabeth de Jesus Posada Luis Izquierdo Dolors Tassies Alexandre-Ferreira Marques Elisa de Lazzari Edelweiss Aldasoro Jose Muñoz Alba Abras Silvia Tebar Montserrat Gallego Igor Correia de Almeida Joan-Carles Reverter Joaquim Gascon |
author_sort |
Maria-Jesus Pinazo |
title |
Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response. |
title_short |
Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response. |
title_full |
Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response. |
title_fullStr |
Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response. |
title_full_unstemmed |
Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response. |
title_sort |
altered hypercoagulability factors in patients with chronic chagas disease: potential biomarkers of therapeutic response. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS Neglected Tropical Diseases |
issn |
1935-2727 1935-2735 |
publishDate |
2016-01-01 |
description |
Thromboembolic events were described in patients with Chagas disease without cardiomyopathy. We aim to confirm if there is a hypercoagulable state in these patients and to determine if there is an early normalization of hemostasis factors after antiparasitic treatment. Ninety-nine individuals from Chagas disease-endemic areas were classified in two groups: G1, with T.cruzi infection (n = 56); G2, healthy individuals (n = 43). Twenty-four hemostasis factors were measured at baseline. G1 patients treated with benznidazole were followed for 36 months, recording clinical parameters and performance of conventional serology, chemiluminescent enzyme-linked immunosorbent assay (trypomastigote-derived glycosylphosphatidylinositol-anchored mucins), quantitative polymerase chain reaction, and hemostasis tests every 6-month visits. Prothrombin fragment 1+2 (F1+2) and endogenous thrombin potential (ETP) were abnormally expressed in 77% and 50% of infected patients at baseline but returned to and remained at normal levels shortly after treatment in 76% and 96% of cases, respectively. Plasmin-antiplasmin complexes (PAP) were altered before treatment in 32% of G1 patients but normalized in 94% of cases several months after treatment. None of the patients with normal F1+2 values during follow-up had a positive qRT-PCR result, but 3/24 patients (13%) with normal ETP values did. In a percentage of chronic T. cruzi infected patients treated with benznidazole, altered coagulation markers returned into normal levels. F1+2, ETP and PAP could be useful markers for assessing sustained response to benznidazole. |
url |
http://europepmc.org/articles/PMC4700971?pdf=render |
work_keys_str_mv |
AT mariajesuspinazo alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT elizabethdejesusposada alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT luisizquierdo alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT dolorstassies alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT alexandreferreiramarques alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT elisadelazzari alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT edelweissaldasoro alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT josemunoz alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT albaabras alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT silviatebar alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT montserratgallego alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT igorcorreiadealmeida alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT joancarlesreverter alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse AT joaquimgascon alteredhypercoagulabilityfactorsinpatientswithchronicchagasdiseasepotentialbiomarkersoftherapeuticresponse |
_version_ |
1725156299809751040 |